SGO: High-volume centers associated with gynecologic cancer survival

Share this content:
SGO: Gynecologic Cancer Survival Up at High-Volume Centers
SGO: Gynecologic Cancer Survival Up at High-Volume Centers

(HealthDay News) -- For women with gynecologic cancers, treatment at high-volume centers is associated with a survival advantage, according to a study presented at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer, held from March 22 to 25 in Tampa, Fla.

Jeff F. Lin, M.D., from the Magee-Women's Hospital at the University of Pittsburgh Medical Center, and colleagues used the National Cancer Data Base to examine the characteristics and outcomes of centers treating high volumes of gynecologic cancer patients. A cohort of 863,156 patients with cervical, uterine, ovarian, vaginal, and vulvar cancer who received treatment at 1,666 centers from January 1998 to December 2011 were identified. The centers were divided into quartiles based on case volumes.

The researchers found that the lowest quartile centers treated a greater proportion of patients over 71 years old and patients with stage IV disease. There was a disease-site survival advantage associated with treatment at top quartile centers, ranging from 2.3 to 34.1 months compared with the lowest-volume centers (P < 0.0005 for all cancers except uterine [P = 0.6]). A 10 percent increased adjusted mortality risk was seen for treatment at lowest-quartile centers.

"Based on this and other studies, we should be trying to steer even more patients to high-volume hospitals," Lin said in a statement.

Press Release
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs